Dr. Yu on the Significance of the PROTECT Study in Prostate Cancer

Video

In Partnership With:

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the significance of the PROTECT study results in prostate cancer.

The 10-year outcomes of a study monitoring, surgery, or radiotherapy for localized prostate cancer were published in the New England Journal of Medicine this past year, which compared active surveillance, radical prostatectomy, and external-beam radiotherapy.

Much of the focus of these results have been on the small survival difference between active surveillance and local therapy, says Yu. But, the quality- of-life data is what is interesting about this trial, Yu says, with patients experiencing better genitourinary and sexual function with 6 months of radiotherapy versus surgery.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD